Alkermes plc (ALKS) vs CG Oncology Inc. (CGON)

A side-by-side comparison of Alkermes plc and CG Oncology Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Alkermes plc logo
ALKS
Alkermes plc
$7.09B
$42.27HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT
CG Oncology Inc. logo
CGON
CG Oncology Inc.
$5.83B
$66.11HealthcareDelayed quote: Oct 6, 2026, 11:25 AM EDT

Total return — ALKS vs CGON

growth of $100 · dividends reinvested · last 3y
ALKS +54.4% (+15.6%/yr)CGON +84.9% (+22.7%/yr)CGON compounded faster over this window
50100150200Start $10020252026$154$185
ALKS CGON

ALKS vs CGON: by the numbers

  • •ALKS is the larger company ($7.09B vs $5.83B market cap).
  • •ALKS is profitable (3.97% net margin) while CGON runs a net loss (-3602.68%).

Metrics side by side

Valuation

MetricALKSCGON
P/E ratio110.37N/A
P/S ratio4.25936.27
P/B ratio3.925.67
EV / EBITDA45.57N/A
FCF yield3.13%N/A

Profitability

MetricALKSCGON
Gross margin84.56%-15.02%
Operating margin17.21%-4722.13%
Net margin3.97%-3602.68%
ROE3.66%-21.80%
ROIC2.12%-24.33%

Growth (annualized)

MetricALKSCGON
Revenue CAGR (5Y)8.68%N/A
FCF CAGR (5Y)20.00%N/A
Total return CAGR (5Y)6.73%N/A

Frequently asked

Is ALKS or CGON more profitable?
ALKS runs the higher net margin — ALKS at 3.97% versus CGON at -3602.68%.

Go deeper

Full ALKS analysisFull CGON analysisInteractive comparison tool

Dig into the metrics

Alkermes P/E ratioAlkermes ROECG Oncology ROEAlkermes operating marginCG Oncology operating marginAlkermes revenue growthCG Oncology revenue growthAlkermes free cash flowCG Oncology free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.